<p>Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study</p>

Abstract

Purpose The aim of this study was to evaluate the prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (DNLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in soft tissue sarcoma (STS) cases treated with pazopanib. Materials and methods The study population included 26 STS cases treated with pazopanib for at least 3 months. NLR, DNLR, LMR, and PLR were evaluated at baseline, and at third month of therapy and also compared with response to pazopanib. Median measurements were taken as cutoff for NLR (4.8), DNLR (3.1), LMR (3.6), and PLR (195). The associations between these cutoff values and survival times (progression-free survival [PFS] and overall survival [OS]) were assessed by Kaplan–Meier curves and Cox proportional models. Results Patients with low pretreatment NLR and DNLR had longer OS ( P =0.022, P =0.018), but low PLR was found to be associated only with longer OS. Additionally, decrease in NLR and DNLR after 3 months of therapy as compared with pretreatment measurements was found to be associated with an advantage for OS ( P =0.021, P =0.010, respectively) and PFS ( P =0.005, P =0.001, respectively). Response to pazopanib; changes in NLR, DNLR, LMR, and PLR; and >3 metastatic sites were found to be independent risk factors in univariate analysis, but NLR was the only independent risk factor in multivariate analysis. Conclusion Low pretreatment and decrease in NLR and DNLR values, and regression/stable disease after 3 months of pazopanib are predictive factors for longer OS and PFS.

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

“…The study included two different cohorts (formerly named typical and malignant SFT) and reported an outcome in PFS, OS, and ORR according to Choi criteria, clearly better than historical control achievement with chemotherapy. Similar to our results, high pretreatment and/or increased NLR values have been previously reported as predictive factors for a shorter PFS and OS in other types of STS treated with pazopanib, such as undifferentiated pleomorphic sarcoma and leiomyosarcoma [ 11 , 12 ]. Likewise, the prognostic role of NLR before treatment has been confirmed in different solid tumours [ 13 ], including STS [ 15 ].…”

“…In addition to tumour cells, neutrophils, macrophages, and lymphocytes infiltrated into the tumour microenvironment can contribute to amplifying inflammatory signalling through cytokines and chemokines. Neutrophils and macrophages secrete tumour-growth-promoting factors, including VEGF, HGF, IL-6, IL-8, MMPs, and elastases [ 12 , 27 ]. Our analysis of gene expression profiles in the tumour microenvironment identified genes implicated in inflammation or immune response, such as PTGS2 and TYK2 .…”

“…Moreover, an increased neutrophil/lymphocyte ratio (NLR) after pazopanib treatment has been independently associated with significantly shorter PFS and OS in some STS types different from SFT [ 11 ]. Additionally, high NLR values have been also associated with adverse survival in many solid tumours [ 12 , 13 , 14 ] and metastasis at diagnosis in STS [ 15 ]. Other peripheral inflammatory indexes, such as high platelet/lymphocyte ratio (PLR), have been associated with worse survival in STS [ 16 ] and other solid tumours [ 17 ] or high red cell distribution width (RDW), which has been associated with worse OS in solid tumours, including osteosarcomas [ 17 , 18 , 19 , 20 , 21 ].…”

The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy

“…Soft tissue sarcoma (STS) is a relatively rare malignant tumor that originates from mesenchymal tissue with a heterogeneous category comprised of more than 50 histologic subtypes. 1 , 2 It accounts for approximately 24,000 new cases annually in China and the incidence is higher in adolescents. 3 , 4 The most common histologic subtypes of STS are undifferentiated sarcoma (US), liposarcoma (LPS), synovial sarcoma (SS) and leiomyosarcoma (LMS), which are associated with different molecular characteristics and behavior features.…”

Prognostic impact of clinical, haematological, and histopathological variables in 102 canine cutaneous perivascular wall tumours

“…CBC parameters have been widely investigated as potential prognostic markers for several malignancies in humans, and the role of NLR in predicting survival for STS patients is well established 7,24‐28 . MacFarlane and colleagues found that NLR was significantly higher in dogs with STS compared with dogs with benign soft tissue tumours, although neither NLR nor leukocyte counts correlated with tumour grade in the STS group 11 .…”